Context Therapeutics Inc. (NASDAQ:CNTX) Short Interest Update

Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) saw a significant increase in short interest in the month of December. As of December 31st, there was short interest totalling 1,530,000 shares, an increase of 55.1% from the December 15th total of 986,300 shares. Approximately 2.6% of the company's shares are sold short. Based on an average daily volume of 501,500 shares, the short-interest ratio is currently 3.1 days.

Context Therapeutics Stock Up 3.2 %

Shares of NASDAQ CNTX traded up $0.03 on Friday, hitting $1.01. The company had a trading volume of 259,944 shares, compared to its average volume of 366,240. Context Therapeutics has a 12-month low of $0.89 and a 12-month high of $2.75. The firm has a market capitalization of $75.75 million, a P/E ratio of -1.11 and a beta of 2.10. The business has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.89.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.11). On average, sell-side analysts anticipate that Context Therapeutics will post -0.51 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently issued reports on CNTX shares. JMP Securities initiated coverage on shares of Context Therapeutics in a research note on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $6.00 price target on shares of Context Therapeutics in a research note on Monday, September 23rd. D. Boral Capital restated a "buy" rating and issued a $9.00 price objective on shares of Context Therapeutics in a report on Wednesday. Finally, Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a report on Wednesday, January 8th. Six research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $6.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Driehaus Capital Management LLC acquired a new position in Context Therapeutics in the 2nd quarter worth $4,527,000. Great Point Partners LLC purchased a new stake in shares of Context Therapeutics during the second quarter worth about $14,876,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics in the second quarter worth about $10,348,000. State Street Corp grew its stake in Context Therapeutics by 21.5% during the 3rd quarter. State Street Corp now owns 111,907 shares of the company's stock valued at $219,000 after purchasing an additional 19,800 shares in the last quarter. Finally, Nantahala Capital Management LLC acquired a new stake in Context Therapeutics during the 2nd quarter valued at approximately $3,881,000. 14.03% of the stock is currently owned by hedge funds and other institutional investors.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.